CLINICAL TRIALS PROFILE FOR YESCARTA
✉ Email this page to a colleague
All Clinical Trials for YESCARTA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03642626 ↗ | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Recruiting | Masonic Cancer Center, University of Minnesota | 2018-12-18 | This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately. | |
| NCT03954106 ↗ | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity | Terminated | Jazz Pharmaceuticals | Phase 2 | 2019-10-04 | This is a prospective, open-label, single-arm study evaluating the safety and efficacy of defibrotide for the prevention of CAR-T-associated neurotoxicity in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) receiving Yescarta. |
| NCT04205838 ↗ | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | Suspended | National Cancer Institute (NCI) | Phase 2 | 2020-03-04 | This phase II trial studies how well anakinra works in preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma that has come back or has not responded to treatment. Immunosuppressive therapy, such as anakinra, is used to decrease the body?s immune response, which may prevent severe chimeric antigen receptor T-cell-related encephalopathy syndrome. |
| NCT04205838 ↗ | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | Suspended | Jonsson Comprehensive Cancer Center | Phase 2 | 2020-03-04 | This phase II trial studies how well anakinra works in preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma that has come back or has not responded to treatment. Immunosuppressive therapy, such as anakinra, is used to decrease the body?s immune response, which may prevent severe chimeric antigen receptor T-cell-related encephalopathy syndrome. |
| NCT04257578 ↗ | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Recruiting | AstraZeneca | Phase 1/Phase 2 | 2020-12-02 | This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma. |
| NCT04257578 ↗ | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2020-12-02 | This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma. |
| NCT04257578 ↗ | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Recruiting | University of Washington | Phase 1/Phase 2 | 2020-12-02 | This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for YESCARTA
Condition Name
| Condition Name for YESCARTA | |
| Intervention | Trials |
| Recurrent Diffuse Large B-Cell Lymphoma | 4 |
| Refractory Diffuse Large B-Cell Lymphoma | 4 |
| Refractory High Grade B-Cell Lymphoma | 3 |
| Recurrent High Grade B-Cell Lymphoma | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for YESCARTA
Trials by Country
Clinical Trial Progress for YESCARTA
Clinical Trial Phase
Clinical Trial Sponsors for YESCARTA
Sponsor Name
